Risk Factors Update Summary

• Research and development expenses are expected to increase substantially from $316.2 million to $441 million.
• Increased dependence on information technology systems and infrastructure, including mobile technologies, may lead to financial loss due to cyberattacks.
• Accumulated deficit increased from $1.2 billion to $1.05 billion.
• Addition of state laws like the California Consumer Privacy Act and GDPR could result in fines up to €20 million.
• Collaboration with Janssen terminated, impacting wind-down activities and development of product candidates.
• Geopolitical risks from ongoing wars between Russia and Ukraine could adversely impact business operations.
• Difficulty in optimizing dosing for product candidates, prioritizing certain candidates, and establishing predictive preclinical models.
• Delay in filing IND applications with the FDA, challenges in obtaining regulatory agreement, and unexpected safety issues.
• Potential delays in manufacturing product candidates due to supply chain issues related to public health crises or disasters.
• Risks associated with unintended changes to DNA and potential adverse effects of genome editing.